{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T03:47:06Z","timestamp":1774928826895,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"9863","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/s0140-6736(12)61900-x","type":"journal-article","created":{"date-parts":[[2012,11,21]],"date-time":"2012-11-21T19:31:57Z","timestamp":1353526317000},"page":"303-312","source":"Crossref","is-referenced-by-count":2394,"title":["Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial"],"prefix":"10.1016","volume":"381","clinical-trial-number":[{"clinical-trial-number":"nct01103323","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Axel","family":"Grothey","sequence":"first","affiliation":[]},{"given":"Eric Van","family":"Cutsem","sequence":"additional","affiliation":[]},{"given":"Alberto","family":"Sobrero","sequence":"additional","affiliation":[]},{"given":"Salvatore","family":"Siena","sequence":"additional","affiliation":[]},{"given":"Alfredo","family":"Falcone","sequence":"additional","affiliation":[]},{"given":"Marc","family":"Ychou","sequence":"additional","affiliation":[]},{"given":"Yves","family":"Humblet","sequence":"additional","affiliation":[]},{"given":"Olivier","family":"Bouch\u00e9","sequence":"additional","affiliation":[]},{"given":"Laurent","family":"Mineur","sequence":"additional","affiliation":[]},{"given":"Carlo","family":"Barone","sequence":"additional","affiliation":[]},{"given":"Antoine","family":"Adenis","sequence":"additional","affiliation":[]},{"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[]},{"given":"Heinz-Josef","family":"Lenz","sequence":"additional","affiliation":[]},{"given":"Richard M","family":"Goldberg","sequence":"additional","affiliation":[]},{"given":"Daniel J","family":"Sargent","sequence":"additional","affiliation":[]},{"given":"Frank","family":"Cihon","sequence":"additional","affiliation":[]},{"given":"Lisa","family":"Cupit","sequence":"additional","affiliation":[]},{"given":"Andrea","family":"Wagner","sequence":"additional","affiliation":[]},{"given":"Dirk","family":"Laurent","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1016\/S0140-6736(12)61900-X_bib2","doi-asserted-by":"crossref","first-page":"v93","DOI":"10.1093\/annonc\/mdq222","article-title":"Advanced colorectal cancer: ESMO clinical practice guidelines for treatment","volume":"21","author":"Van Cutsem","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/S0140-6736(12)61900-X_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clcc.2011.05.005","article-title":"An update on the current and emerging targeted agents in metastatic colorectal cancer","volume":"11","author":"Chu","year":"2012","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/S0140-6736(12)61900-X_bib5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/S0140-6736(12)61900-X_bib6","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/bjc.2012.153","article-title":"Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study","volume":"106","author":"Strumberg","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/S0140-6736(12)61900-X_bib7","series-title":"EORTC QLQ-C30 Scoring Manual","year":"2001"},{"key":"10.1016\/S0140-6736(12)61900-X_bib8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(12)61900-X_bib9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/S0140-6736(12)61900-X_bib10","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2010.29.4496","article-title":"Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787\/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma","volume":"29","author":"Hecht","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(12)61900-X_bib11","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2010.29.5436","article-title":"Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787\/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/S0140-6736(12)61900-X_bib12","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1200\/jco.2012.30.4_suppl.386","volume":"30","author":"Siu","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(12)61900-X_bib13","doi-asserted-by":"crossref","unstructured":"Tabernero J, Garcia-Carbonero R, K\u00f6hne CH, et al. A phase 2b, double-blind, randomized study evaluating the efficacy and safety of sorafenib (SOR) compared with placebo (PBO) when administered in combination with chemotherapy (modified FOLFOX6) for first-line treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC). The RESPECT trial. European Multidisciplinary Cancer Congress; Stockholm, Sweden; Sept 24\u201327, 2011. 19LBA.","DOI":"10.1016\/S0959-8049(11)70118-6"},{"issue":"suppl 4","key":"10.1016\/S0140-6736(12)61900-X_bib14","article-title":"Results of the X-PECT study: a phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC)","volume":"30","author":"Bendell","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(12)61900-X_bib15","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1200\/JCO.2012.42.5355","article-title":"Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III)","volume":"30","author":"Schmoll","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(12)61900-X_bib16","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1200\/JCO.2012.42.6031","article-title":"Cediranib plus FOLFOX\/CAPOX versus placebo plus FOLFOX\/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II)","volume":"30","author":"Hoff","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(12)61900-X_bib17","doi-asserted-by":"crossref","unstructured":"Zopf D, Scholz A, Fichtner I, et al. Regorafenib (BAY 73-4506): a broad-spectrum tumor deactivator with high combinability potential and antimetastasis activity. American Association for Cancer Research 102nd Annual Meeting; Orlando, FL, USA; April 2\u20135, 2011. 4262.","DOI":"10.1158\/1538-7445.AM2011-4262"},{"key":"10.1016\/S0140-6736(12)61900-X_bib18","doi-asserted-by":"crossref","unstructured":"Schmieder R, Hoffmann J, Bhargava A, et al. Regorafenib (BAY 73-4506): antimetastatic activity in a mouse model of colorectal cancer. American Association for Cancer Research 103rd Annual Meeting; Chicago, IL, USA; March 31\u2013April 4, 2012. 2337.","DOI":"10.1158\/1538-7445.AM2012-2337"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014067361261900X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014067361261900X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T17:42:25Z","timestamp":1562348545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014067361261900X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":16,"journal-issue":{"issue":"9863","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S014067361261900X"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(12)61900-x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717965145.793466450","asserted-by":"object"}]},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}